davila research lab

The Davila Lab aims to understand the cellular and molecular signals that promote the generation of potent and long-lasting tumor-specific T cell responses. Early preclinical studies demonstrated thatformulating vaccines to include toll like receptor agonists together with peptides representing tumor antigens induced potent CD8 cytotoxic T cell responses and were effective at treating tumors in a prophylactic and therapeutic setting. We continue to exploit the T cell’s ability to recognize and destroy tumors.

lab personnel

selected publications

Jitao Guo, Elena Muse, Allison J. Christians, Steven J. Swanson, and Eduardo Davila.  Using an anticancer drug cocktail of MK2206, Nut7441, and tramatenib to improve dendritic cell-based cancer vaccines. Cancer Immunol Res. Accepted May 2019

Suk Lee Y, Davila E, Zhang T, Milmoe HP, Vogel SN, Bromberg JS, Scalea JR. Myeloid-derived suppressor cells are bound and inhibited by anti-thymocyte globulin. Innate Immun. 2019 Jan;25(1):46-59. doi: 10.1177/1753425918820427. PMID: 30782043; PMCID: PMC6830891.

Geng D, Ciavattone N, Lasola JJ, Shrestha R, Sanchez A, Guo J, Vlk A, Younis R, Wang L, Brown AJ, Zhang Y, Velasco-Gonzalez C, Tan AC, Davila E. Induction of IRAK-M in melanoma induces caspase-3 dependent apoptosis by reducing TRAF6 and calpastatin levels. Commun Biol. 2020 Jun 12;3(1):306. doi: 10.1038/s42003-020-1033-y. PMID: 32533049.

Neuwelt A, Al-Juhaishi T, Davila E, Haverkos B. Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas. Blood Adv. 2020 Sep 8;4(17):4256-4266. doi: 10.1182/bloodadvances.2020001966. PMID: 32898250; PMCID.

View All Publications

CMS Login